Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly. The Danish drugmaker said Tuesday that pre-filled pens and vials of long-acting and short-acting insulins will see price reductions. They include Levemir, Novolin, NovoLog and NovoLog Mix70/30. Novo also will drop the list price of some unbranded products to match the lower price of the branded insulins. The price cuts go into effect Jan.